UK's Immunocore Q4 KIMMTRAK sales rise 24%

Immunocore Holdings

25/02/2026 12:19

Overview

Biotechnology firm's Q4 net sales of KIMMTRAK rose 24% yr/yr

Adjusted EPS for FY 2025 missed analyst expectations

Net income for FY 2025 missed analyst estimates

Outlook

Immunocore expects moderating revenue growth for KIMMTRAK in 2026

Result Drivers

KIMMTRAK SALES GROWTH - Q4 sales rose due to increased volumes in US and Europe and global expansion

CLINICAL PIPELINE ADVANCEMENT - Co progressing trials in melanoma and other tumor types, expanding beyond oncology

EXPANSION STRATEGY - Co focused on expanding patient reach for KIMMTRAK and lifecycle management

Company press release: ID:nGNE4d9CnK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
Miss
-$0.71
-$0.34 (14 Analysts)
FY Net Income
Miss
-$35.51 mln
-$18.34 mln (15 Analysts)
FY Operating Income
Miss
-$45.35 mln
-$41.26 mln (17 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Immunocore Holdings PLC is $68.00, about 101.9% above its February 24 closing price of $33.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)